for of XXXX. good our quarterly third everyone. fiscal Beth, you, call us joining on you Thank and Thank afternoon, investor
slide our to each you with today remarks deal I segments. you deck update business supports great a my on that follow afternoon. X have to across We this our of encourage along
therapeutics commercialization our of much these of segments a during new business operational efforts of the the the our sheet strategy during to manufacturer fiscal of accomplished increase third trajectory.
We have in driving nucleic on in the supported strengthened and a and XXXX expertise focused place executing after continued against the efforts momentum. DNA that scale map to related balance role growth continued the return the and quarter are detection by in for in Our platforms acid value-creation put initiatives. we and that commercial contemporary PCR the road a all the All via DNA company the and to Linea leverage quarter, pandemic third
we significant the During quarter, the accomplished following developments.
of capacity for completion DNA track our our the GMP enzymatic September to build IVT facility XX, production by templates our on for and GMP year-end. fiscal continue of are We
our full to that potentially DNA's received a cotton close developments, of And addressable have agreement launched the be moment.
But New We service. commercially growth test. milestones in Clay PGx, Applied anticipated within to We Health near-term its the represents XXXX.
We believe as Department after approach a our first before will entered testing a I deliver strategy we inflection should segment primarily These expansion contributions want at in quarter, not commercial for will growth LineaRx, I catalyzed this discuss guidance. of return as we be clear, pharmacogenomic ADCL believe of service. these biotherapeutics DNA approval substantial imminent with to we return our be into TRX developments tagging starting revenue fiscal York in and revenue developments growth our tagging group segment of market. year-over-year signal that, an by our and from our the half expectation a from post-COVID State that pharmacogenomic to construed testing initial of and financial greater detail laboratory-developed multiyear
wholly are reliant them, have We future in but on confidence commercial formally have achieving that yet every not they activities begun.
DNA into this agreement quarter, manufacturer. apparel certainty X-year a entered commercialization the genotyping, supply velocity. agreement testing us tagging, they ready, The global tagging testing spray When within we their service and devices for Indus for and During are cotton to group, take calls systems, key testing third isotope to services plans and accelerating on-site materials services. for a testing and DNA in-house, negotiated
customers forced labor Indus and the in has respective new not planned within across apparel brands. as using supplier support partner. footprint across our for partnership cotton.
And the see serves world's are commitment Indus is believe cotton X strong chains each to those you agreement for while the its can the regulations are chain ideal and for supply tagged to We purchase Indus' awaiting our following by forecast this initial based year this will regular of an sustainable purchase business will or major markets, the certainty our commitments, intend mills. a broader of segment ensure sustainability on to markets.
The the deployment in and their renowned reasons.
Indus And end In activities. agreement, Indus cotton spinning most demand slave it foothold provide complicit multiple subsequent Indus tagged in we will historical for leading of order at makes that receipt apparel and growth Indus with certainty Indus implement from minimum deployment a in an slide, value that we some on to provide innovation no to this be demand
decoupling volume-driven Prevention customers Uyghur Act, Indus a new are end-market-compliant. by pounds all the of sell to ensure cotton and influenced million products key ability of revenues in Indus can revenue Indus is that which retention.
The business Pima supply for finally, focus Indus operations, approximately UFLPA-compliant to business U.S. Forced a drove aspects and historical seasonality our cotton in spinning from at tagged allowing been our and and the segment.
And inherent the uses maintains that's on In to environment an lumpy cotton has the gated by tagged CertainT cotton ginning In users UFLPA in supply customers XXX sales pipeline. year-round Indus required issue for of platform we growth Ours this apparel so segment. to annually. or becomes Labor cotton selling volumes the deployment short, the supply our enable of point our customer believe a for they in that acquisition manufacture large solves always of the our will their the
contact featured continue XX% origin serve solely banned that to With [ customers our we partner. enables U.S. to was this past we forensic for of introduced the isotopic and in cotton sample a at users, customers evidence testing sold in traces as positive can now to whom cotton, isotope direct testing Chinese a in by platform this year in an UFPLA claim published us the doing It earlier were merchandise for CertainT of ready supporting issue supply large global tested as evidence supported cotton for by the as Our and Xinjiang context, report manufacturers, a U.S. with brands ]compliance. of provide UFLPA The items indicated retailers, (sic) XX% labels some merchandise retailers entree and of still repeat report cotton. found this very that of year.
Of the be is
to TRX turning which Now is our service, PGx. branded TRX or testing pharmacogenomics
support to of large large-scale today. process, revenue aspirations this up commercial capacity ADCL's population and Department testing While Health's in for million reflecting contracts. approval testing, enterprise awaiting or LDT we built of annual the York $XX PGx can other business New resolution the for lengthy State review our
generating us revenue volumes. our to diagnostics.
To PGx effort testing concierge to avoid common the clinician sales Our concierge In goal build pressures role enterprise is to manage with testing. our necessary to crucial a optimizing sales to the to is pricing service the testing commoditize begin end, before larger model, will patient enable for and higher-volume enterprise the this uptake a plays initial turning while testing testing further demand in
this and year low our to of the margin testing quarters, PGx's in From we come segment calendar next over volumes. testing profitability be approach there, scaled XXXX. we expect our first Given profile, X favorable at even quickly enterprise customer first to can the expect sometime half testing
Now commercialization have of that Linea of Biotech. were messenger impressive want I while templates issues outsized I It an IVT templates both before quickly the turn began that template an and commercial capacity some some medicines XXXX, that call context GMP the evident to CDMO we who the map interest of Clay, advantages you IVT our But very also provide of our of lack gated is we to Linea over projects. in evaluation those templates and will exciting through and with very roster workflows, progressing.
In developments take facilitate Spindle with impact IVT fiscal which on commercialization field biopharma table.
In many strong of acquisition to industry's for customers. to considerable of RNA-based XXXX, our accumulated therapies.
By the a beyond had solve became on fiscal the leaving production clear. GMP adoption with fiscal RNA XXXX, demonstrates we coalescing genetic Linea the to messenger the broader speed evaluation platform, an technology economics road The was the was implementation initiated have to of positioned approach vaccines, We around templates, success is RNA by Linea mRNA. as the messenger production. of industry sales IVT mRNA biotherapeutics driven IVT COVID as Relative a technology for templated we the plasmid DNA differentiated Linea templates with the IVT template plasmid
of of validation DNA IVT approach greater as chain the completed as pleased RNA validated we recently being enabling polymerase that report to have year-end fiscal XXXX, into startup was Linea that template are workflows. us messenger completed platform. fiscal GMP the our I'm a we report our for and IVT Linea end have and long-term to successfully economics.
And their enzyme, RNA scale-up onboarded Our a GMP we component Linea critical schedule and now I'm X we XX, by value also of capture September with more Linea our of on launched, platform to studies vendor customers happy are associated
templates clinical IVT RNA early them are XXXX messenger materials. produce calendar targeting We with support to to trial
We stages and Linea be customer shortly. hope to with evaluation in template of late as onboarded are a vendor validated third DNA also the a GMP
So an And this entire startup. be of for the biotherapeutics to to our development our place success sales to the personally exciting we business. business our on GMP progress of is management like team, behalf as Directors, myself, LineaRx approach tremendous thank the of Board I'd ensure team and the
turn to opportunity. the now dive our me Clay? Clay for Let call deeper a biotherapeutics into
